BACKGROUND AND OBJECTIVE: The consumption of oral antineoplastics -and more particularly of @entity669 -kinase inhibitors (TKI)- has increased in recent years. These therapies show a better tolerance but still, the nutritional alterations related to their daily and chronic clinical use are under investigation. This study assesses the effects of TKI on the intake, nutritional status and micronutrients as well as the @entity1 quality of life. METHODS: A prospective longitudinal study was conducted including adult @entity1 having started some TKI treatment from July 2012 to June 2013, and a 6 month follow-up period was established. Demographic pharmacotherapeutic, nutritional and biochemical variables were collected and also a EORTC-QLQ30 questionnaire at baseline, first, third and sixth month of treatment. RESULTS: 31 @entity1 were included in the study. The percentage of @entity353 at treatment baseline was statistically matched to the results on the @entity1 -generated Global Subjective Assessment. Appetite decreased after one month of treatment, and so did the calorie consumption; 62.1% of the @entity1 lost weight, 55.5% on the third month and 70.6% on the sixth month. 6-17% of the @entity1 suffered from @entity3147 to some degree during the follow-up period and a decrease of @entity460 , @entity1391 and @entity1760 plasma levels was detected. The emotional scale was the one with a lowest score in EORTC QLQ-30, and @entity1295 and lack of appetite were the most common symptoms at treatment baseline, progressively increasing those of @entity390 , @entity391 and @entity294 . DISCUSSION: @entity1 treated with TKI did not show a relevant @entity3147 . Considering the results, it is important to take into account @entity353 at treatment baseline; it is also important to control @entity460 and @entity1391 levels during treatment, to advise and counsel the @entity1 on the GI effects ( @entity390 , @entity391 and @entity294 ) and emotionally reinforce the @entity1 .

[Nutritional assessment and quality of life of oncology outpatients initiating treatment with XXXX  -kinase inhibitors].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomits'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity669 :: (CHEBI:18186,Chemical) :: ['tyrosine']
